07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

ALD-301: Phase II started

Cytomedix disclosed in its 4Q12 earnings that it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate a single administration of 10, 1 mL intramuscular injections of ALD-301 in about 80 patients. The trial...
23:16 , Jul 2, 2010 |  BC Extra  |  Financial News

Aldagen amends IPO

Aldagen Inc. (Durham, N.C.) amended its IPO and now hopes to raise up to $40 million through the sale of units in an IPO underwritten by Boenning & Scattergood; Ladenburg Thalmann; and National Securities. Each...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

ALD-101: Development discontinued

Aldagen disclosed in an SEC filing that in January it discontinued development of lead candidate ALD-101 to improve cord blood transplantation in pediatric patients with inherited metabolic disorders. The company said the agency was unlikely...
00:37 , May 7, 2010 |  BC Extra  |  Company News

Aldagen discontinues ALD-101, amends IPO

Aldagen Inc. (Durham, N.C.) disclosed in an SEC filing that in January it discontinued development of lead clinical candidate ALD-101 to improve cord blood transplantation in pediatric patients with inherited metabolic disorders. The company said...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

ALD-301: Additional Phase I/II data

Additional data from a double-blind Phase I/II trial in 21 patients showed that ALD-301 significantly improved clinical status as measured by a 0.64-point reduction from baseline to 12 weeks in the Rutherford category (p=0.05) compared...
08:00 , Nov 2, 2009 |  BioCentury  |  Finance

Ebb & Flow

Last week's low-money down acquisition of Metabasis Therapeutics Inc. (NASDAQ:MBRX) by cancer and inflammation play Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is the latest example of a structured acquisition with contingent payouts over time. Ligand could get...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

ALD-301 regulatory update

Aldagen received an SPA from FDA for a double-blind, placebo-controlled Phase III trial to evaluate ALD-301 for 6 months to treat advanced critical limb ischemia (CLI) in patients with no revascularization options. The company hopes...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

ALD-301: Phase I/II data

In a double-blind Phase I/II trial, ALD-301 was well-tolerated and produced no serious adverse events. After 12 weeks, 4 of 11 ALD-301 patients no longer had critical limb ischemia. ALD-301 patients also had improved blood...